RHD: Blood group Rh(D) polypeptide
May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane.
- Drugs that act on it: 4
- Approved: 0
- In phases 1 to 3: 4
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on RHD, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 3
- Other 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Symphogen A/S125%
| Atorolimumab | Phase 2 | — | Antibody | OtherBlood group Rh(D) polypeptide other | 0 |
| Morolimumab | Phase 2 | — | Antibody | Inhibitor | 0 |
| Roledumab | Phase 2 | — | Antibody | Inhibitor | 0 |
| Rozrolimupab | Phase 2 | Symphogen A/S | Other | Inhibitor | 0 |
- Rh deficiency syndrome0.39
- Rheumatoid arthritis0.31
- Anemia0.21
- Tinnitus0.19
- Blood group antigen abnormality0.18
- Pregnancy induced alloimmunization0.14
- Hemolytic disease of fetus and newborn, RH-induced0.12
- Neoplasm0.10
- Metabolic disease0.10
- Alloimmunization0.09
- Autoimmune thrombocytopenic purpura0.08
- Gluthathione peroxidase deficiency0.06
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712996, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q02161, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets